AbbVie Presents New Late-Breaking Data Analyses of Skyrizi (risankizumab) for Crohn’s Disease at DDW 2021

 AbbVie Presents New Late-Breaking Data Analyses of Skyrizi (risankizumab) for Crohn’s Disease at DDW 2021

Shots:

  • The P-III ADVANCE and MOTIVATE studies involves assessing Risankizumab (600/ 1200mg) vs PBO in a mixed population of patients who had responded inadequately or are intolerant to conventional (non-bio-IR) or biologic (bio-IR) therapy and patients who had responded inadequately or were intolerant to biologic (bio-IR) therapy respectively
  • Both the doses met its co-1EPs of clinical remission and endoscopic response @12wks. in both the studies. Detailed results were presented at DDW 2021
  • Risankizumab is an IL-23 inhibitor, currently being evaluated as a treatment for adults with moderate to severe Crohn’s disease and other immune-mediated conditions

Click here to­ read full press release/ article | Ref: Abbvie | Image: Wall Street Journal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post